tbuckley/cabot-search huggingface dataset:
Psychiatric morbidity and suicidal behaviour in low- and middle-income countries: A systematic review and meta-analysis
Authors: Duleeka Knipe, A. Jess Williams, Stephanie Hannam-Swain, Stephanie Upton, Katherine Brown, Piumee Bandara, Shu-Sen Chang, Nav Kapur
Journal: PLoS Medicine (2019)

Background Psychiatric disorders are reported to be present in 80% to 90% of suicide deaths in high-income countries (HIC), but this association is less clear in low- and middle-income countries (LMIC). There has been no previous systematic review of this issue in LMIC. The current study aims to estimate the prevalence of psychiatric morbidity in individuals with suicidal behaviour in LMIC. Methods and findings PubMed, PsycINFO, and EMBASE searches were conducted to identify quantitative research papers (any language) between 1990 and 2018 from LMIC that reported on the prevalence of psychiatric morbidity in suicidal behaviour. We used meta-analytic techniques to generate pooled estimates for any psychiatric disorder and specific diagnosis based on International classification of disease (ICD-10) criteria. A total of 112 studies (154 papers) from 26 LMIC (India: 25%, China: 15%, and other LMIC: 60%) were identified, including 18 non-English articles. They included 30,030 individuals with nonfatal suicidal behaviour and 4,996 individuals who had died by suicide. Of the 15 studies (5 LMIC) that scored highly on our quality assessment, prevalence estimates for psychiatric disorders ranged between 30% and 80% in suicide deaths and between 3% and 86% in those who engaged in nonfatal suicidal behaviour. There was substantial heterogeneity between study estimates. Fifty-eight percent (95% CI 46%–71%) of those who died by suicide and 45% (95% CI 30%–61%) of those who engaged in nonfatal suicidal behaviour had a psychiatric disorder. The most prevalent disorder in both fatal and nonfatal suicidal behaviour was mood disorder (25% and 21%, respectively). Schizophrenia and related disorders were identified in 8% (4%–12%) of those who died by suicide and 7% (3%–11%) of those who engaged in nonfatal suicidal behaviour. In nonfatal suicidal behaviour, anxiety disorders, and substance misuse were identified in 19% (1%–36%) and 11% (7%–16%) of individuals, respectively. This systematic review was limited by the low number of high-quality studies and restricting our searches to databases that mainly indexed English language journals. Conclusions Our findings suggest a possible lower prevalence of psychiatric disorders in suicidal behaviour in LMIC. We found very few high-quality studies and high levels of heterogeneity in pooled estimates of psychiatric disorder, which could reflect differing study methods or real differences. There is a clear need for more robust evidence in order for LMIC to strike the right balance between community-based and mental health focussed interventions.
The national tragedy of rising childhood mortality in Dominica: 15 years and counting
Authors: Golnaz Naderkhani, Oluremilekun Oyefolu, Marwa Ali, Dulmi Gunawardana, Cedric Mahailet, Ashley Massicotte
Journal: The Lancet Global Health (2019)

Although the world has celebrated accelerated mean annual reductions in child mortality over the past two decades, even in the most poorly resourced countries,1 child survival trends in Dominica have remained in sharp contrast to the rest of the world since 2003. Dominica is the only country in recorded history where childhood mortality has been consistently and considerably on the rise for the past 15 years and counting.
Increased Incidence of Symptomatic Hyponatremia with Voriconazole Prophylaxis during Cyclophosphamide Based Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplantation
Authors: Anant Gokarn, Vikram Gota, Gautam Goyal, Alok Gupta, Sachin Punatar, Pravin Patil, Krunal Kavathiya, Kamal Pathak, Murari Gujjar, Libin Mathew, Bhausaheb Bagal, Sadhana Kannan, Navin Khattry
Journal: Blood (2014)
John Michael Campbell Gray
Authors: D J Unsworth
Journal: BMJ (2019)

John Michael Campbell Gray grew up in north Belfast during the Troubles and attended his local grammar school, Belfast Royal Academy. In keeping with a family tradition, he did his first degree at Queen’s College, Oxford, where he studied biochemistry. He received an open entrance scholarship awarded for excellence in entrance examination and interview.

Although John was from a family of doctors, he was initially reluctant to follow this well worn path. On completing his studies at Oxford, he returned home to Northern Ireland and became a full time residential worker at the Corrymeela Christian Community, promoting reconciliation and peace building. John loved connecting with people in every walk of life and later spent time working in …
Characterization of Acute Myeloid Leukemia with PTPN11 Mutation - The Mutation Is Closely Associated with NPM1 Mutation but Inversely Related to FLT3/ITD.
Authors: Hsin-An Hou, Wen-Chien Chou, Chien-Yuan Chen, Liang-In Lin, Jih-Luh Tang, Mei-Hsuan Tseng, Chi-Fei Huang, Rong-Jing Chiou, Fen-Yu Lee, Ming-Chih Liu, Hwei-Fang Tien
Journal: Blood (2007)
Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Authors: Jatin J. Shah, Lei Feng, Elisabet E. Manasanch, Donna Weber, Sheeba K Thomas, Francesco Turturro, Nina Shah, Uday R. Popat, Yago Nieto, Qaiser Bashir, Silvia C Munoz, Ashley Landry, Kathleen Mendoza, Richard E. Champlin, Muzaffar H. Qazilbash, Robert Z. Orlowski
Journal: Blood (2015)
Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed
Authors: Jacob D Soumerai, Kurt S Bantilan, Ai Ni, Connie Batlevi, Anna Alperovich, Katy Smith, Zhitao Ying, Amanda R Copeland, Matthew J. Matasar, David J Straus, John F Gerecitano, Paul A Hamlin, Steven M Horwitz, Carol S Portlock, Maria Lia Palomba, Craig H Moskowitz, Alison J Moskowitz, Ariela Noy, Craig S Sauter, Anita Kumar, Andrew M Intlekofer, Philip Caron, Pamela Drullinsky, Anas Younes, Andrew D Zelenetz
Journal: Blood (2016)
Variations of Noxa Levels Caused by p38 MAPK Signaling Result In Heterogeneous Sensitivity to ABT-737 In CD40L-Stimulated CLL Cells
Authors: Jacqueline M Tromp, Christian R Geest, Judith Elias, Jacoline van Laar, Marinus H.J. Van Oers, Eric Eldering
Journal: Blood (2010)
Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study
Authors: Elliott Vichinsky, Amal El-Beshlawy, Azzam Alzoebie, Annie Kamdem, Suzanne Koussa, Thirachit Chotsampancharoen, Andreas Bruederle, Jackie Han, Mohsen Elalfy
Journal: Blood (2016)
Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial
Authors: Gareth J Morgan, Faith E. Davies, Walter M Gregory, Sue E. Bell, Alexander J Szubert, Mark T. Drayson, John Ashcroft, Roger G. Owen, Gordon Cook, Fiona M. Ross, Graham H. Jackson, Nigel H. Russell, J. Anthony Child
Journal: Blood (2010)
Src Kinases Act Downstream Akt and Are Required for the Transforming Properties of Constitutively Activated Forms of STAT5A and STAT5B
Authors: Remy Nyga, Lea Savay, Ingrid Marcq, Aline Regnier, Gandhi Damaj, Jacques Rochette, Fabrice Gouilleux, Kaiss Lassoued
Journal: Blood (2011)
Increased Angiogenic Property Of Human Peripheral Blood Monocytes By ex Vivo Culture With c-Mpl Agonists In Hindlimb Ischemia Mouse Model
Authors: Junpei Sasajima, Toru Kawamoto, Yoshiaki Sugiyama, Yusuke Mizukami, Yasuyuki Iuchi, Toshifumi Ashida, Hiroki Tanabe, Yoshihiro Torimoto, Yutaka Kohgo
Journal: Blood (2013)
Abstract 179: Sanctifying Sadness: Conducting a Moment of Silence at Time of Patient’s Death is Associated With Decreased Staff Burnout
Authors: Joyce R Foresman-Capuzzi, Meghan Sheehan, Meghan Buckley, David Burgess, Sharon Larson, Christopher Jones
Journal: Circulation (2018)

Introduction: Anecdotal stories exist about pausing to honor resuscitation teams and the patient after in-hospital deaths. It is unknown whether conducting a moment of silence (MOS) at the time of death impacts caregivers. Objectives: We sought to assess whether implementing a scripted and brief, secular MOS ritual after a patient dies reduces healthcare team burnout or improves resiliency. Methods: We conducted an unblinded, prospective cohort study of multidisciplinary intensive care unit (ICU) staff from two hospitals, implementing the MOS in one ICU with the other a control. The Maslach Burnout Inventory (MBI) was administered pre- and post-implementation and focus groups obtained qualitative feedback. Changes in median composite scores were assessed for comparisons using the Wilcoxon Signed-Rank Test. Results: We obtained 25 pre-post paired responses. The implementation ICU’s respondents included more physicians (36.4% vs 0%, p=0.032) with no difference in other measured characteristics. MBI scores pre-implementation were similar. After implementation, intervention staff had a significant decrease in median Depersonalization subscore on the MBI (median: 8 vs 6; p=0.045). MBI Emotional Exhaustion subscore trended toward improvement (median: 26 vs 24; p=0.075) and the Personal Accomplishment subscore was unchanged (median: 37 vs 34; p=0.18). No significant changes over time in MBI scores were noted in the staff from the control ICU. Qualitative feedback was universally positive, resulting in dissemination of the MOS system-wide. Conclusion: Implementation of a brief, secular MOS ritual in a community hospital’s ICU was associated with decreased burnout, specifically in the Depersonalization domain. This may be due to the creation of a formalized, group time for clinicians, nurses and multidisciplinary staff to attend to their own emotions after a patient death. Rollout of the scripted MOS intervention across the 5-hospital system, including distinctive phraseology for the pediatric, peri-operative, and maternity settings, shows widespread buy-in including within health system leadership. Larger studies and those conducted in other healthcare settings would increase confidence in the generalizability of results.
Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM
Authors: Yago Nieto, Roland Bassett, Paolo Anderlini, Chitra M. Hosing, Amin M. Alousi, Uday R. Popat, Borje S. Andersson, Benigno C. Valdez, Elizabeth J. Shpall, Sairah Ahmed, Muzaffar Qazilbash, Maria Guillermo, Yasuhiro Oki, Michelle A. Fanale, Fredrick B. Hagemeister, Bouthaina S. Dabaja, Chelsea C Pinnix, Sarah A Milgrom, Priti Tewari, Richard E. Champlin, Roy Jones
Journal: Blood (2015)
Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients
Authors: Aisha N. Hasan, Susan E. Prockop, Guenther Koehne, Ekaterina Doubrovina, Richard J. O'Reilly
Journal: Blood (2014)
Neurocognition and quality of life in patients with intracranial metastases – contributing factors and impact on clinical outcome
Authors: Najmus Iqbal, Tara Daisley-Devoy, Michelle Smalley, Anne Johnson, John Staffurth, Richard Wise, James Powell
Journal: Neuro-Oncology (2019)

Abstract Cognitive impairment at diagnosis is prevalent in patients with brain metastases (BM). Neurocognitive function (NCF) decline following radiotherapy is well described in this patient cohort, but the impact of baseline NCF on clinical outcome and survival is less well understood. In this study we describe NCF in patients at baseline before undergoing stereotactic radiosurgery without whole brain radiotherapy and explore its impact on overall survival and explore possible causative factors. Baseline NCF data was collected in patients with 1–3 BM and WHO performance status 0–2. Patients underwent NCF assessments according to the RANO group and included Hopkin’s verbal learning test, controlled oral word association test, trail making test A and B and digit span. We collected quality of life (QoL) data using EORTC QLQ30/BN20 questionnaires and recorded functional assessment of cancer therapy scores. 31 patients underwent neurocognitive testing with mean age of 65 years and median overall survival was 10 months. 21 patients had a single metastasis. The most common primary site was lung (12) followed by melanoma (7). 64% of patients exhibited impaired NCF at baseline in at least 1 domain with a Z-score of &gt;1 and this was associated with lower overall survival. Other factors associated with lower overall survival were presence of seizures, steroid use and larger tumour volume. In this study impaired NCF at baseline was associated with lower overall survival. Intracranial disease burden and the presence of seizures were also associated with worse NCF and worse survival indicating that these may be important causative factors to consider.
Early Clinical Manifestations, Presence Of a Single Bantou Haplotype and High Baseline Reticulocyte Count Predict Severity In a Sickle Cell Anemia Newborn Cohort
Authors: Corinne Pondarre, Annie Kamdem, Cécile Arnaud, Serge Pissard, Josiane Michau, Clément Tassel, Isabelle Hau, Ralph Epaud, Francoise Bernaudin
Journal: Blood (2013)
Novel Influenza A (2009/H1N1) Infection In Patients with Hematological Malignancies During the 2009 Pandemic Outbreak: Early Antiviral Treatment Improves Survival
Authors: Karen Joan Vigil, Javier A Adachi, Ying Jiang, Uday Popat, Mohsen Ghadimi Mahani, Bruno P Granwehr, Susan Gaeta, Imrana Malik, Richard Champlin, Isaam I Raad, Roy F Chemaly
Journal: Blood (2010)
Interphase Fluorescence In Situ Hybridization (FISH) with an IgH Probe Is Important in the Management of Patients with a Clinical Diagnosis of Chronic Lymphocytic Leukemia (CLL).
Authors: Grzegorz S. Nowakowski, Gordon W. Dewald, Sarah F. Paternoster, Stephanie R. Fink, Stephanie A. Smoley, Ellen D. Remstein, James D. Hoyer, Robert L. Phyliky, Timothy G. Call, Tait D. Shanafelt, Clive S. Zent
Journal: Blood (2004)
Lack of Response to Vaccination in MGUS and Stable Myeloma.
Authors: Rao H Prabhala, Yvonne A Efebera, Saem Lee, Andrew J Han, Dheeraj Pelluru, Puru Nanjappa, Samir Amin, Christine Pai, Irene Ghobrial, Robert L Schlossman, Jacob Laubach, Mariateresa Fulciniti, Paul Richardson, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2009)
Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Acute Myeloid Leukemia
Authors: Marc Cartellieri, Irene Michalk, Malte von Bonin, Thomas Krüger, Slava Stamova, Stefanie Koristka, Claudia Arndt, Anja Feldmann, Marc Schmitz, Martin Wermke, Dirk Lindemann, Martin Bornhäuser, Gerhard Ehninger, Michael Bachmann
Journal: Blood (2011)
A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas
Authors: Wendy Béguelin, Matt Teater, Connie Corcoran, Michelle Hamline, Randy D. Gascoyne, Ross L. Levine, Omar Abdel-Wahab, Rita Shaknovich, Olivier Elemento, Vivian J. Bardwell, Ari Melnick
Journal: Blood (2015)
Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial
Authors: Sophie de Guibert, Marie-Sarah Dilhuydy, Loic Ysebaert, Laurence Sanhès, Sylvain Choquet, Therese Aurran-Schleinitz, Romain Guieze, Beatrice Mahe, Nicolas Daguindau, Carla Araujo, Hussam Saad, Emmanuelle Ferrant, Bruno Cazin, Pierre Feugier, Brigitte Dreyfus, Delmer Alain, Stéphane Lepretre, Magali Le Garff-Tavernier, Véronese Lauren, Anna Schuh, Bruno Pereira, Veronique Leblond, Olivier Tournilhac
Journal: Blood (2014)
Hydroxycarbamide (HU), Sickle Cell Disease and Pregnancy, a Multicentric Retrospective Study
Authors: Laure Joseph, Anoosha Habibi, Giovanna Cannas, Stephanie Ngo, Sylvain Le Jeune, Ersi Voskaridou, Elena Foïs, Caroline Makowski, Nathalie Lemonne, Narcisse Elenga, Yves Ville, Alexandra Benachi, Robert Girot, Marina Cavazzana, Jean-Antoine Ribeil
Journal: Blood (2016)
Characterization of DLBCL-Derived Exosomes and Investigation of Their Biological Properties
Authors: Sarah C. Rutherford, Seema Sawh, Ashish Saxena, Jennifer Ishii, Maria D. Dominguez, Nyasha Chambwe, Eloisi Caldas Lopes, Xabier Agirre, Doron Betel, Rita Shaknovich
Journal: Blood (2014)
Government’s no-deal readiness report still leaves questions unanswered, says BMA
Authors: Gareth Iacobucci
Journal: BMJ (2019)

The UK government has published its no-deal readiness report outlining its preparations for the UK leaving the European Union without a deal on 31 October.1

The 156 page report covers all areas likely to be affected, including border controls, public services, industry, and citizens’ rights. It says that the government has “intensified preparations” on all fronts since 24 July 2019, when Boris Johnson became prime minister.

From a healthcare perspective, however, the BMA said that the report leaves many questions unanswered, including how the supply of critical medicines …
Use of biologics in addition to chemotherapy in the treatment of elderly Medicare patients with stage IV metastatic colon cancer.
Authors: C. Daniel Mullins, Fenghao Wang, Kaloyan A. Bikov, Brian S. Seal, Nader Hanna
Journal: Journal of Clinical Oncology (2013)

e14602 Background: On February 12 and 26, 2004, the FDA approved bevacizumab and cetuximab, respectively, two biologic drugs for the first–line treatment of metastatic colorectal cancer (mCC), followed by panitumumab, another biologic approved on September 27, 2006. NCCN guidelines suggest that biologics may be added to fluorouracil and leucovorin (5-FU/LV), irinotecan (IRI), or oxaliplatin (OX), yet a number of recent articles raise questions regarding the added benefit of biologics on top of a backbone chemotherapy regimen, which might affect the utilization pattern of biologics. To examine the adoption of biologics, we document the rate of treatment with biologics in addition to backbone chemotherapy as first-line treatment (Tx1) of mCC. Methods: This study uses the Surveillance, Epidemiology and End Results (SEER)-Medicare data and examines mCC patients diagnosed in 2003-2007 who received chemotherapy with or without biologics as Tx1. Due to the small sample size of cases involving the combined use of irinotecan and oxaliplatin (IROX) as Tx1, IROX patients were excluded from this study. The remaining 2995 observations are broken down by regimen and by year of Tx1 initiation (Table). Results: The use of biologics (90% of which was bevacizumab) in addition to chemotherapy as part of Tx1 exploded from 9% in 2004 to 55% in 2005. Utilization was highest (62%) in 2006 and fell slightly in 2007 to 57%. Of all cases utilizing biologics, 67% were oxaliplatin-based regimens, 19% were fluorouracil-based regimens and 15% were irinotecan-based regimens. Conclusions: In the first few years following FDA approval, the use of biologics in addition to backbone chemotherapy increased rapidly as first-line treatment of elderly Medicare metastatic colon cancer patients, leveling out at around half of all patients receiving chemotherapy. Biologics use has been most common among patients treated with oxaliplatin. [Table: see text]
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells
Authors: Beatris Mastelic-Gavillet, Blanca Navarro Rodrigo, Laure Décombaz, Haiping Wang, Giuseppe Ercolano, Rita Ahmed, Leyder Elena Lozano, Angela Ianaro, Laurent Derré, Massimo Valerio, Thomas Tawadros, Patrice Jichlinski, Tu Nguyen-Ngoc, Daniel E. Speiser, Grégory Verdeil, Nicolas Gestermann, Olivier Dormond, Lana Kandalaft, George Coukos, Camilla Jandus, Christine Ménétrier-Caux, Christophe Caux, Ping-Chih Ho, Pedro Romero, Alexandre Harari, Selena Vigano
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Several mechanisms are present in the tumor microenvironment (TME) to impair cytotoxic T cell responses potentially able to control tumor growth. Among these, the accumulation of adenosine (Ado) contributes to tumor progression and represents a promising immunotherapeutic target. Ado has been shown to impair T cell effector function, but the role and mechanisms employed by Ado/Ado receptors (AdoRs) in modulating human peripheral and tumor-infiltrating lymphocyte (TIL) function are still puzzling. <h3>Methods</h3> CD8<sup>+</sup> T cell cytokine production following stimulation was quantified by intracellular staining and flow cytometry. The cytotoxic capacity of tumor infiltrating lymphocytes (TILs) was quantified by the chromium release assay following co-culture with autologous or anti-CD3-loaded tumor cell lines. The CD8<sup>+</sup> T cell metabolic fitness was evaluated by the seahorse assay and by the quantification of 2-NBDG uptake and CD71/CD98 upregulation upon stimulation. The expression of AdoRs was assessed by RNA flow cytometry, a recently developed technology that we validated by semiquantitative RT-PCR (qRT-PCR), while the impact on T cell function was evaluated by the use of selective antagonists and agonists. The influence of Ado/AdoR on the PKA and mTOR pathways was evaluated by phosphoflow staining of p-CREB and p-S6, respectively, and validated by western blot. <h3>Results</h3> Here, we demonstrate that Ado signaling through the A2A receptor (A2AR) in human peripheral CD8<sup>+</sup> T cells and TILs is responsible for the higher sensitivity to Ado-mediated suppression of T central memory cells. We confirmed that Ado is able to impair peripheral and tumor-expanded T cell effector functions, and we show for the first time its impact on metabolic fitness. The Ado-mediated immunosuppressive effects are mediated by increased PKA activation that results in impairment of the mTORC1 pathway. <h3>Conclusions</h3> Our findings unveil A2AR/PKA/mTORC1 as the main Ado signaling pathway impairing the immune competence of peripheral T cells and TILs. Thus, p-CREB and p-S6 may represent useful pharmacodynamic and efficacy biomarkers of immunotherapies targeting Ado. The effect of Ado on T cell metabolic fitness reinforces the importance of the adenosinergic pathway as a target for next-generation immunotherapy.
Identification of Two Distinct Poor Prognostic Subgroups Related to High Expression of BMP2 or PRDM16 in Pediatric AML
Authors: Yusuke Hara, Norio Shiba, Genki Yamato, Jun Okubo, Kentaro Ohki, Myoung-Ja Park, Manabu Sotomatsu, Daisuke Tomizawa, Tomohiko Taki, Akitoshi Kinoshita, Nobutaka Kiyokawa, Takashi Taga, Hirokazu Arakawa, Akio Tawa, Keizo Horibe, Souichi Adachi, Yasuhide Hayashi
Journal: Blood (2016)
Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi
Authors: Stefano Luminari, Maria Cecilia Goldaniga, Marina Cesaretti, Sara Rattotti, Marco Frigeni, Alessandra Tedeschi, Paola Picardi, Simone Ferrero, Federica Cavallo, Giuseppina Cabras, Michele Merli, Emanuele Cencini, Donato Mannina, Gianluca Gaidano, Angela Ferrari, Giuseppina Ricciuti, Rosanna Ciancia, Francesca Re, Marcia Torresan Delamain, Inês B Pereira, Athina Lymboussaki, Vittoria Tarantino, Massimo Federico, Luca Arcaini
Journal: Blood (2015)
Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).
Authors: Deborah A. Thomas, Jorge Cortes, Susan O’Brien, Stefan Faderl, Farhad Ravandi, Gullermo Garcia-Manero, Francis Giles, Miloslav Beran, Charles Koller, William Wierda, Srdan Verstovsek, Alessandra Ferrajoli, Steven Kornblau, Michael Keating, Michael Andreeff, Hagop Kantarjian
Journal: Blood (2005)